New Tools for Formidable Foes: Strategies for Management of Unresected Soft Tissue Sarcomas

Some patients with soft tissue sarcomas may be inoperable due to medical comorbidity or might decline radical or amputative surgeries due to undesirable functional outcomes. However, the relative lower radiosensitivity of sarcomas pose significant challenge for control and symptomatic relief of unresected, often bulky, soft tissue sarcomas. To achieve greater local control and symptom palliation than conventional radiotherapy, efforts over the recent decade have explored options including particle therapy, SBRT, lattice/GRID therapy, and combined modality treatment. This panel provides an overview of published clinical results of these novel strategies for unresected sarcomas and developments on the horizon.

Topics:

  1. Cases/Introduction to Management of Unresected Soft Tissue Sarcoma
    Daniel J. Indelicato, MD, FASTRO, FRCR
  2. Historical Outcomes with Standard Fractionation Photon Therapy
    Benoit Alligen, MD, MS
  3. Novel Fractionation and Radiobiological Techniques with Photon Therapy
    Arash Olyie Naghavi, MD, MS
  4. The Promise of Particle Therapy 
    Sahaja Acharya, MD
  5. Q and A
    Daniel J. Indelicato, MD, FASTRO – Moderator
    Full Panel

This activity is available from April 28, 2026, through 11:59 p.m. Eastern time on April 27, 2028. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists, surgeons, physicists, radiation biologists, residents, orthopedic oncologists and surgical oncologists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the radiobiological challenges in radiating unresected sarcomas of different histologies.
  • Explain potential options for improving outcomes for radiating unresected sarcomas. 
  • Discuss the pros and cons of various strategies for radiating unresected sarcomas. 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
04/28/2026
Course expires: 
04/27/2028
Cost:
$149.00
Rating: 
0

Moderator:  

  • Daniel J. Indelicato, MD, FASTRO, FRCR, is employed by the University of Florida. Dr. Indelicato has no relevant financial relationship with ineligible companies to disclose. 

Speakers: 

  • Benoit Allignet, MD, MS, is employed by Centre Leon Berard and Inserm. Dr. Allignet has no relevant financial relationship with ineligible companies to disclose.
  • Arash Olyie Naghavi, MD, MS, is employed by H. Lee Moffitt Cancer Center and Research Institute. Dr. Naghavi has no relevant financial relationship with ineligible companies to disclose.
  • Sahaja Acharya, MD, is employed by Johns Hopkins University School of Medicine. Dr. Acharya has no relevant financial relationship with ineligible companies to disclose.  

Planners: 

  • Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until April 27, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.